A unique confluence of key factors fuels China’s leadership and momentum ahead of the US in AI health technology. A combination of massive data availability, low-cost labor to prepare this machine learning information, and the need to offset doctor shortages contribute to growth in this... Read More
A Chinese government program to buy pharmaceuticals and medical devices in bulk has been expanded to include a larger selection of devices, putting fierce competitive pressure on foreign medical device companies seeking to tap into the vast country’s market. First launched in 2018... Read More
Multinational pharmaceutical firms are taking advantage of fledgling low-cost commercial insurance initiatives in China to more readily access the country’s vast and rapidly growing market for their products—and to price them more competitively. Under strict eligibility rules on pharmaceuticals and medical... Read More
As part of an ongoing crackdown by China on business practices, it says lead to unfair competition, the central government is strengthening law enforcement of monopoly practices in the pharmaceutical industry. The announcement by the ministry of industry and information technology... Read More
This article was originally published on MedTech Intelligence. 3-D printing has revolutionized product customization and digital manufacturing in various industries. In many instances, it is not only faster and less expensive than alternative manufacturing methods but also numerous types of material can... Read More
Prices of drugs sold in China will drop by 61.7% on average this year, as the latest update to China’s National Reimbursement Drug List (NRDL) goes into effect. But while the price cut—the most significant slash since 2017 — is a blow... Read More
To download this report, please click on PBM’s Report on Orphan Drugs and Rare Diseases in China Read More
The latest round of negotiations between the Chinese government and pharmaceutical firms has yielded massive price cuts for consumers in the country on more than 65 new brand-name drugs in return for access to the second-largest pharmaceutical market in the world. The... Read More
More and more device purchasing in China is done via government tenders and procurement. China is now signaling it may ease rules that prohibit foreign companies from obtaining lucrative government procurement deals. That could be good news for foreign medical device manufacturers... Read More
China’s National Medical Products Administration (NMPA) in November announced the creation of a platform to collect information related to all active pharmaceutical ingredients (APIs) in circulation in the country. The new platform will allow NMPA, which drafts laws and regulations for drugs,... Read More